

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

EB1

RRID:CVCL_2027

Type: Cell Line

Proper Citation

RRID:CVCL_2027

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2027

Proper Citation: RRID:CVCL_2027

Description: Cell line EB1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: EBV-related Burkitt lymphoma

Defining Citation: [PMID:2998993](#), [PMID:3518877](#), [PMID:4894370](#), [PMID:5884338](#), [PMID:6018567](#), [PMID:7316467](#), [PMID:8515068](#), [PMID:8558920](#), [PMID:12145705](#), [PMID:14090852](#), [PMID:14293790](#), [PMID:14293791](#), [PMID:20215515](#), [PMID:20454443](#), [PMID:22460905](#), [PMID:24590883](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: African; Ugandan., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: EB1

Synonyms: EB-1, Epstein-Barr-1

Cross References: BTO:BTO_0003000, CLO:CLO_0002869, CLO:CLO_0002870, EFO:EFO_0002172, CLDB:cl1127, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:HTB-60, BioSample:SAMN03472402, BioSample:SAMN03473402, BioSample:SAMN10987945, cancercellines:CVCL_2027, Cell_Model_Passport:SIDM00862, CLS:300403, Cosmic:1086328, Cosmic:1818341,

DepMap:ACH-000877, DSMZ:ACC-80, DSMZCellDive:ACC-80, EGA:EGAS00001000610, GEO:GSM827341, GEO:GSM886991, GEO:GSM888060, IARC_TP53:21315, IGRhCellID:EB1, LiGeA:CCLE_384, LINCS_LDP:LCL-2030, Pharmacodb:EB1_313_2019, Progenetix:CVCL_2027, Wikidata:Q54831741

ID: CVCL_2027

Record Creation Time: 20220427T215826+0000

Record Last Update: 20260815T232726+0000

Ratings and Alerts

No rating or validation information has been found for EB1.

No alerts have been found for EB1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Hu H, et al. (2026) ??Pharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia. Med (New York, N.Y.), 7(3), 100966.

Beauchemin H, et al. (2025) Inhibiting the RNA helicase DDX3X in Burkitt lymphoma induces oxydative stress and impedes tumor progression in xenografts. Frontiers in cell and developmental biology, 13, 1642006.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer cell, 41(12), 2136.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell reports. Medicine, 2(7), 100350.